 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 Logo of Antibe Therapeutics | |
| Company type | Publicly traded corporation |
|---|---|
| TSX: ATE | |
| Industry | Pharmaceuticals |
| Founded | 1 January 2010  |
| Headquarters | Toronto , Canada |
Key people | Dan Legault JD, CEO; Alain Wilson, CFO; Dr. John L. Wallace, Chief Scientific Officer; Joseph Stauffer, Chief Medical Officer |
| Website | www |
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology.[1] Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.[2]
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.[3]
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.[4]
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange.
- ^ "Antibe Therapeutics". Archived from the original on 2021-11-17. Retrieved 2021-11-23.
- ^ "Stocks". Bloomberg News. Archived from the original on 2017-12-17. Retrieved 2021-11-23.
- ^ "Antibe's Non-Opioid Pain Drug Otenaproxesul Looks Good in Phase IIb Trials". American Council on Science and Health. August 5, 2020. Archived from the original on June 26, 2021. Retrieved November 23, 2021.
- ^ "Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain". American Council on Science and Health. 2021-03-21. Archived from the original on 2023-06-01. Retrieved 2023-06-01.